1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Cervarix (Prophylactic Human PapillomaVirus Vaccines) - Forecast and Market Analysis to 2022

Cervarix (Prophylactic Human PapillomaVirus Vaccines) - Forecast and Market Analysis to 2022

  • March 2014
  • -
  • GlobalData
  • -
  • 44 pages

Summary

Table of Contents

Cervarix (Prophylactic Human PapillomaVirus Vaccines) - Forecast and Market Analysis to 2022

Summary

The first prophylactic vaccine for immunization against human papillomavirus (HPV) became available in 2006. The global HPV vaccines market is now well established, yet vaccine coverage rates amongst the traditional target population of adolescent girls remain persistently low. Initially HPV vaccines were developed and marketed solely to protect against cervical cancer. In recent years the role of HPV in other cancers has been increasingly recognized which has facilitated a shift towards vaccinating a wider population, most significant has been the inclusion of males in routine vaccine recommendations in some countries. The current HPV vaccines market is dominated by one major player, Merck’s Gardasil, with GlaxoSmithKline’s (GSK’s) HPV vaccine Cervarix providing the only competition. The introduction of Merck’s nine-valent vaccine (V503) is set to change the future landscape of the HPV vaccines sector.

Cervarix is manufactured and marketed by GSK, and consists of recombinant VLPs of the L1 capsid proteins from HPV strains 16 and 18, produced using a Baculovirus expression system. VLPs are combined with GSK’s proprietary AS04 adjuvant, adsorbed on aluminum hydroxide. Cervarix is administered as a three-dose schedule with the second and third doses at one and six months following the first dose, respectively.

Scope

- Overview of HPV, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Cervarix including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Cervarix for the top nine countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Canada and Australia

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for HPV
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Cervarix performance
- Obtain sales forecast for Cervarix from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, Canada and Australia)

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
Get This Report
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
2017-2021 World Sexually-Transmitted Disease (STD) Diagnostics Market: Chancroid, Chlamydia, Gonorrhea, Herpes, HPV, Syphilis--Supplier Shares, Sales Forecasts, Competitive Strategies, Innovative Technologies, Instrumentation

2017-2021 World Sexually-Transmitted Disease (STD) Diagnostics Market: Chancroid, Chlamydia, Gonorrhea, Herpes, HPV, Syphilis--Supplier Shares, Sales Forecasts, Competitive Strategies, Innovative Technologies, Instrumentation

  • $ 9600
  • Industry report
  • January 2017
  • by Venture Planning Group

About this Report This report presents a detailed analysis of the STD market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan.  Current scientific views on epidemiology and etiology are ...

2017 Competing in the Global Sexually-Transmitted Disease (STD)Testing Market

2017 Competing in the Global Sexually-Transmitted Disease (STD)Testing Market

  • $ 9600
  • Industry report
  • March 2017
  • by Venture Planning Group

Complete report $9,600.  DataPack (test volumes, sales forecasts, supplier shares) $6,200. This new 350-page report from VPGMarketResearch.com contains 90 tables and provides analysis of the global s ...

2017-2021 Sexually-Transmitted Diseases (STD) Diagnostic Testing Market

2017-2021 Sexually-Transmitted Diseases (STD) Diagnostic Testing Market

  • $ 6200
  • Industry report
  • February 2017
  • by Venture Planning Group

Complete report $9,600.  DataPack (test volumes, sales forecasts, supplier shares) $6,200. This new 350-page report from VPGMarketResearch.com contains 90 tables and provides analysis of the global s ...


Download Unlimited Documents from Trusted Public Sources

Healthcare Industry in the US - Forecast

  • March 2017
    51 pages
  • HIV AIDS  

    Infectious Dise...  

  • United States  

View report >

Infectious Disease and Eye Disease Statistics in Tanzania

  • March 2017
    20 pages
  • Infectious Dise...  

    HIV AIDS  

  • Tanzania  

    Netherlands  

View report >

Healthcare Industry in the US - Forecast

  • March 2017
    51 pages
  • HIV AIDS  

    Infectious Dise...  

  • United States  

View report >

Related Market Segments :

Sexually Transmitted Disease

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.